{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:50:07Z","timestamp":1775058607291,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201494"],"award-info":[{"award-number":["82201494"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471376"],"award-info":[{"award-number":["82471376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00415-025-13523-0","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:58:32Z","timestamp":1763535512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment"],"prefix":"10.1007","volume":"272","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7637-1305","authenticated-orcid":false,"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"13523_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"13523_CR2","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J, Lin DY, Zeng D et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142:1310\u20131323. https:\/\/doi.org\/10.1093\/brain\/awz054","journal-title":"Brain"},{"issue":"9451","key":"13523_CR3","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106\u20132112. https:\/\/doi.org\/10.1016\/S0140-6736(04)17551-X","journal-title":"Lancet"},{"key":"13523_CR4","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","volume":"81","author":"Y Jiao","year":"2013","unstructured":"Jiao Y, Fryer JP, Lennon VA et al (2013) Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 81:1197\u20131204. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a6cb5c","journal-title":"Neurology"},{"key":"13523_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","volume":"387","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Lucchinetti CF (2022) Neuromyelitis optica spectrum disorder. N Engl J Med 387:631\u2013639. https:\/\/doi.org\/10.1056\/NEJMra1904655","journal-title":"N Engl J Med"},{"key":"13523_CR6","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/1352458513515085","volume":"20","author":"N Collongues","year":"2014","unstructured":"Collongues N, Marignier R, Jacob A et al (2014) Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler 20:1086\u20131094. https:\/\/doi.org\/10.1177\/1352458513515085","journal-title":"Mult Scler"},{"issue":"6","key":"13523_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000607","volume":"6","author":"M Sepulveda","year":"2019","unstructured":"Sepulveda M, Delgado-Garc\u00eda G, Blanco Y, Sola-Valls N, Martinez-Lapiscina EH, Armangu\u00e9 T, Montejo C, Pulido-Valdeolivas I, Martinez-Hernandez E, Ari\u00f1o H, Escudero D, Ruiz-Garc\u00eda R, Llufriu S, Dalmau J, Graus F, Saiz A (2019) Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. Neurol Neuroimmunol Neuroinflamm 6(6):e607. https:\/\/doi.org\/10.1212\/NXI.0000000000000607","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13523_CR8","doi-asserted-by":"publisher","first-page":"1575613","DOI":"10.3389\/fimmu.2025.1575613","volume":"16","author":"JR Kretschmer","year":"2025","unstructured":"Kretschmer JR, Tkachenko D, K\u00fcmpfel T et al (2025) Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study). Front Immunol 16:1575613. https:\/\/doi.org\/10.3389\/fimmu.2025.1575613","journal-title":"Front Immunol"},{"key":"13523_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120039","volume":"431","author":"A Papathanasiou","year":"2021","unstructured":"Papathanasiou A, Tanasescu R, Tench CR, Rocha MF, Bose S, Constantinescu CS, Jacob S (2021) Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. J Neurol Sci 431:120039. https:\/\/doi.org\/10.1016\/j.jns.2021.120039","journal-title":"J Neurol Sci"},{"key":"13523_CR10","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1177\/1352458520981736","volume":"27","author":"G Macaron","year":"2021","unstructured":"Macaron G, Khoury J, Bena J et al (2021) Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. Mult Scler 27:1749\u20131759. https:\/\/doi.org\/10.1177\/1352458520981736","journal-title":"Mult Scler"},{"key":"13523_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16178","volume":"31","author":"W Luo","year":"2024","unstructured":"Luo W, Shi Z, Kong L, Wang X, Zhou H (2024) Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: a retrospective cohort study. Eur J Neurol 31:e16178. https:\/\/doi.org\/10.1111\/ene.16178","journal-title":"Eur J Neurol"},{"key":"13523_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102515","volume":"46","author":"LJ Cai","year":"2020","unstructured":"Cai LJ, Zhang Q, Zhang Y, Chen HX, Shi ZY, Du Q, Zhou HY (2020) Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 46:102515. https:\/\/doi.org\/10.1016\/j.msard.2020.102515","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"13523_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00415-015-7766-8","volume":"262","author":"M Krumbholz","year":"2015","unstructured":"Krumbholz M, van Hofstadt- Oy U, Angstwurm K et al (2015) Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol 262(5):1379\u20131384. https:\/\/doi.org\/10.1007\/s00415-015-7766-8","journal-title":"J Neurol"},{"key":"13523_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12883-015-0417-y","volume":"15","author":"Z Mao","year":"2015","unstructured":"Mao Z, Yin J, Zhong X et al (2015) Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population. BMC Neurol 15:160. https:\/\/doi.org\/10.1186\/s12883-015-0417-y","journal-title":"BMC Neurol"},{"key":"13523_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","volume":"267","author":"E Carnero Contentti","year":"2020","unstructured":"Carnero Contentti E, Daccach Marques V, Soto de Castillo I et al (2020) Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort. J Neurol 267:1260\u20131268. https:\/\/doi.org\/10.1007\/s00415-020-09699-2","journal-title":"J Neurol"},{"issue":"4","key":"13523_CR16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/ene.15239","volume":"29","author":"L Wang","year":"2022","unstructured":"Wang L, Tan H, Huang W, Chang X, ZhangBao J, Zhou L, Lu C, Wang M, Lu J, Zhao C, Quan C (2022) Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies. Eur J Neurol 29(4):1128\u20131135. https:\/\/doi.org\/10.1111\/ene.15239","journal-title":"Eur J Neurol"},{"key":"13523_CR17","doi-asserted-by":"publisher","first-page":"1056944","DOI":"10.3389\/fimmu.2022.1056944","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, Sun Q, Yi F et al (2022) Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder. Front Immunol 13:1056944. https:\/\/doi.org\/10.3389\/fimmu.2022.1056944","journal-title":"Front Immunol"},{"key":"13523_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.859276","volume":"13","author":"J Yu","year":"2022","unstructured":"Yu J, Yan S, Niu P, Teng J (2022) Relatively early and late-onset neuromyelitis optica spectrum disorder in central China: clinical characteristics and prognostic features. Front Neurol 13:859276. https:\/\/doi.org\/10.3389\/fneur.2022.859276","journal-title":"Front Neurol"},{"key":"13523_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104517","volume":"70","author":"W Min","year":"2023","unstructured":"Min W, Zhang L, Wang S, Xue M, Guo C, Zhu M (2023) Clinical characteristics of late-onset neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 70:104517. https:\/\/doi.org\/10.1016\/j.msard.2023.104517","journal-title":"Mult Scler Relat Disord"},{"key":"13523_CR20","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/jnnp-2024-333644","volume":"95","author":"KH Kim","year":"2024","unstructured":"Kim KH, Chung YH, Min JH et al (2024) Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study. J Neurol Neurosurg Psychiatry 95:1168\u20131175. https:\/\/doi.org\/10.1136\/jnnp-2024-333644","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13523_CR21","doi-asserted-by":"publisher","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","volume":"94","author":"J Poupart","year":"2020","unstructured":"Poupart J, Giovannelli J, Deschamps R et al (2020) Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology 94:e1645\u2013e1656. https:\/\/doi.org\/10.1212\/WNL.0000000000009245","journal-title":"Neurology"},{"key":"13523_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211056710","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Zhou J, Li Y et al (2021) Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Ther Adv Neurol Disord 14:17562864211056710. https:\/\/doi.org\/10.1177\/17562864211056710","journal-title":"Ther Adv Neurol Disord"},{"key":"13523_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102869","volume":"50","author":"M Velasco","year":"2021","unstructured":"Velasco M, Zarco LA, Agudelo-Arrieta M et al (2021) Effectiveness of treatments in neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature. Mult Scler Relat Disord 50:102869. https:\/\/doi.org\/10.1016\/j.msard.2021.102869","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"13523_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12937-0","volume":"272","author":"X Chen","year":"2025","unstructured":"Chen X, Wang R, Li R et al (2025) A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder. J Neurol 272(3):194. https:\/\/doi.org\/10.1007\/s00415-025-12937-0","journal-title":"J Neurol"},{"issue":"2","key":"13523_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3988\/jcn.2024.0485","volume":"21","author":"SH Kim","year":"2025","unstructured":"Kim SH, Min JH, Kim SM et al (2025) Evaluating Rituximab failure rates in neuromyelitis optica spectrum disorder: a nationwide real-world study from South Korea. J Clin Neurol 21(2):131\u2013136. https:\/\/doi.org\/10.3988\/jcn.2024.0485","journal-title":"J Clin Neurol"},{"key":"13523_CR26","doi-asserted-by":"publisher","first-page":"1559118","DOI":"10.3389\/fneur.2025.1559118","volume":"16","author":"J Zhou","year":"2025","unstructured":"Zhou J, Yang X, Wang X et al (2025) Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. Front Neurol 16:1559118. https:\/\/doi.org\/10.3389\/fneur.2025.1559118","journal-title":"Front Neurol"},{"issue":"10","key":"13523_CR27","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/acn3.70160","volume":"12","author":"Z Javed","year":"2025","unstructured":"Javed Z, Du M, Rensel M et al (2025) Real world effectiveness and tolerability of novel monoclonal antibodies and rituximab for NMOSD. Ann Clin Transl Neurol 12(10):2152\u20132157. https:\/\/doi.org\/10.1002\/acn3.70160","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"13523_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O et al (2024) <article-title update=\"added\">Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)-revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol 271(1):141\u2013176. https:\/\/doi.org\/10.1007\/s00415-023-11910-z","journal-title":"J Neurol"},{"key":"13523_CR29","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1007\/s00415-024-12382-5","volume":"271","author":"R Wang","year":"2024","unstructured":"Wang R, Sun D, Zhang Q et al (2024) Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder. J Neurol 271:4503\u20134512. https:\/\/doi.org\/10.1007\/s00415-024-12382-5","journal-title":"J Neurol"},{"key":"13523_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ene.13186","volume":"24","author":"H Chen","year":"2017","unstructured":"Chen H, Qiu W et al (2017) Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 24:219\u2013226. https:\/\/doi.org\/10.1111\/ene.13186","journal-title":"Eur J Neurol"},{"key":"13523_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578151","volume":"382","author":"R Wang","year":"2023","unstructured":"Wang R, Sun DR, Du Q, Zhang Y, Chen HX, Wang XF, Kong LY, Luo WQ, Shi ZY, Zhou HY (2023) Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder. J Neuroimmunol 382:578151. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578151","journal-title":"J Neuroimmunol"},{"key":"13523_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1352458515587752","volume":"22","author":"IH Jeong","year":"2016","unstructured":"Jeong IH, Park B, Kim SH et al (2016) Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 22:329\u2013339. https:\/\/doi.org\/10.1177\/1352458515587752","journal-title":"Mult Scler"},{"key":"13523_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111137","volume":"135","author":"Q Sun","year":"2025","unstructured":"Sun Q, Li J, Tian D (2025) Clinical characteristics of late-onset neuromyelitis optica spectrum disorder in China. J Clin Neurosci 135:111137. https:\/\/doi.org\/10.1016\/j.jocn.2025.111137","journal-title":"J Clin Neurosci"},{"key":"13523_CR34","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1177\/1352458516685416","volume":"23","author":"JM Seok","year":"2017","unstructured":"Seok JM, Cho HJ, Ahn SW et al (2017) Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea. Mult Scler 23:1748\u20131756. https:\/\/doi.org\/10.1177\/1352458516685416","journal-title":"Mult Scler"},{"issue":"6","key":"13523_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208051","volume":"102","author":"EF Mouresan","year":"2024","unstructured":"Mouresan EF, Mentesidou E, Berglund A et al (2024) Clinical characteristics and long-term outcomes of late-onset multiple sclerosis: a Swedish nationwide study. Neurology 102(6):e208051. https:\/\/doi.org\/10.1212\/WNL.0000000000208051","journal-title":"Neurology"},{"key":"13523_CR36","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834\u20131849. https:\/\/doi.org\/10.1093\/brain\/aws109","journal-title":"Brain"},{"issue":"8","key":"13523_CR37","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1111\/ene.14901","volume":"28","author":"K Nakahara","year":"2021","unstructured":"Nakahara K, Nakane S, Nagaishi A, Narita T, Matsuo H, Ando Y (2021) Very late onset neuromyelitis optica spectrum disorders. Eur J Neurol 28(8):2574\u20132581. https:\/\/doi.org\/10.1111\/ene.14901","journal-title":"Eur J Neurol"},{"issue":"12","key":"13523_CR38","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","volume":"79","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Joseph J et al (2008) Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 79(12):1368\u20131374. https:\/\/doi.org\/10.1136\/jnnp.2008.145805","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"13523_CR39","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1177\/1352458519866613","volume":"26","author":"NA Schwehr","year":"2020","unstructured":"Schwehr NA, Kuntz KM, Butler M, BeAMS Study Group et al (2020) Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. Mult Scler 26(12):1510\u20131518. https:\/\/doi.org\/10.1177\/1352458519866613","journal-title":"Mult Scler"},{"key":"13523_CR40","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1177\/1352458520988637","volume":"27","author":"F Dahlke","year":"2021","unstructured":"Dahlke F, Arnold DL, Aarden PL et al (2021) Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): age is a key contributor to presentation. Mult Scler 27:2062\u20132076. https:\/\/doi.org\/10.1177\/1352458520988637","journal-title":"Mult Scler"},{"issue":"13","key":"13523_CR41","doi-asserted-by":"publisher","first-page":"e1334","DOI":"10.1212\/WNL.0000000000012603","volume":"97","author":"MwKoch","year":"2021","unstructured":"MwKoch, Mostert J, Zhang Y et al (2021) Association of age with contrast-enhancing lesions across the multiple sclerosis disease spectrum. Neurology 97(13):e1334\u2013e1342. https:\/\/doi.org\/10.1212\/WNL.0000000000012603","journal-title":"Neurology"},{"issue":"8","key":"13523_CR42","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/ene.15862","volume":"30","author":"E Coerver","year":"2023","unstructured":"Coerver E, Janssens S, Ahmed A, Wessels M, van Kempen Z, Jasperse B, Barkhof F, Koch M, Mostert J, Uitdehaag B, Killestein J, Strijbis E (2023) Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up. Eur J Neurol 30(8):2385\u20132392. https:\/\/doi.org\/10.1111\/ene.15862","journal-title":"Eur J Neurol"},{"key":"13523_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104212","volume":"68","author":"N Apiraksattayakul","year":"2022","unstructured":"Apiraksattayakul N, Songwisit S, Owattanapanich W, Tisavipat N, Siritho S, Prayoonwiwat N, Rattanathamsakul N, Jitprapaikulsan J (2022) AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review. Mult Scler Relat Disord 68:104212. https:\/\/doi.org\/10.1016\/j.msard.2022.104212","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"13523_CR44","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1111\/ene.15355","volume":"29","author":"W Huang","year":"2022","unstructured":"Huang W, Wang L, Xia J, Li W, Wang M, Yu J, Li Q, Wang B, Pan J, Du L, Ma J, Tan H, Chang X, Lu C, Zhao C, Lu J, Zhou L, ZhangBao J, Quan C (2022) Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder. Eur J Neurol 29(8):2343\u20132354. https:\/\/doi.org\/10.1111\/ene.15355","journal-title":"Eur J Neurol"},{"key":"13523_CR45","doi-asserted-by":"publisher","first-page":"16727","DOI":"10.1038\/s41598-020-73882-8","volume":"10","author":"S Songwisit","year":"2020","unstructured":"Songwisit S, Kosiyakul P, Jitprapaikulsan J et al (2020) Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep 10:16727. https:\/\/doi.org\/10.1038\/s41598-020-73882-8","journal-title":"Sci Rep"},{"issue":"22","key":"13523_CR46","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","volume":"99","author":"P Barreras","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, Fitzgerald KC, Levy M, Pardo CA, Newsome SD, Mowry EM, Calabresi PA, Sotirchos ES (2022) Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology 99(22):e2504\u2013e2516. https:\/\/doi.org\/10.1212\/WNL.0000000000201260","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13523-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:29:19Z","timestamp":1765812559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13523-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["13523"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13523-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Medical Ethics Committee of West China Hospital, Sichuan University, and all participants provided informed consent prior to their inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"771"}}